Cargando…
Diabetic patients with COVID-19 need more attention and better glycemic control
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic disease spreading all over the world and has aroused global concerns. The increasing mortality has revealed its severity. It is important to distinguish severe patients and provide appropriate treatment and care to prevent damages. Diabet...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754170/ https://www.ncbi.nlm.nih.gov/pubmed/33384770 http://dx.doi.org/10.4239/wjd.v11.i12.644 |
_version_ | 1783626141345513472 |
---|---|
author | Xu, Ming Yang, Wen Huang, Tao Zhou, Jun |
author_facet | Xu, Ming Yang, Wen Huang, Tao Zhou, Jun |
author_sort | Xu, Ming |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic disease spreading all over the world and has aroused global concerns. The increasing mortality has revealed its severity. It is important to distinguish severe patients and provide appropriate treatment and care to prevent damages. Diabetes is reported to be a common comorbidity in COVID-19 patients and associated with higher mortality. We attempted to clarify the relationship between diabetes and COVID-19 patients’ severity. AIM: To determine the role of type 2 diabetes in COVID-19 patients. METHODS: To study the relationship between diabetes and COVID-19, we retrospectively collected 61 patients’ data from a tertiary medical center in Wuhan. All the patients were diagnosed with laboratory-confirmed COVID-19 and admitted to the center from February 13 to March 1, 2020. Patients’ age, sex, laboratory tests, chest computed tomography findings, capillary blood glucose (BG), and treatments were collected and analyzed. Fisher exact test was used for categorical data. Univariate and multivariate logistic regressions were used to explore the relationship between clinical characteristics and patients’ severity. RESULTS: In the 61 patients, the comorbidity of type 2 diabetes, hypertension, and heart diseases were 24.6% (15 out of 61), 37.7% (23 out of 61), and 11.5% (7 out of 61), respectively. The diabetic group was related to more invasive treatments (P = 0.02) and severe status (P = 0.003). In univariate logistic regression, histories of diabetes (OR = 7.13, P = 0.003), hypertension (OR = 3.41, P = 0.039), and hepatic dysfunction (OR = 7.69, P = 0.002) were predictors of patients’ severity while heart disease (OR = 4.21, P = 0.083) and large lung involvement (OR = 2.70, P = 0.093) also slightly exacerbated patients’ conditions. In the multivariate analysis, diabetes (OR = 6.29, P = 0.016) and hepatic dysfunction (OR = 5.88, P = 0.018) were risk factors for severe patients. Diabetic patients showed elevated BG in 61.7% of preprandial tests and 33.3% of postprandial tests, revealing the limited control of glycemia in COVID-19 patients. CONCLUSION: A history of type 2 diabetes is correlated with invasive treatments and severe status. Suboptimal glycemic control and hepatic dysfunction have negative effects on severity status and may lead to the exacerbation of COVID-19 patients. |
format | Online Article Text |
id | pubmed-7754170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-77541702020-12-30 Diabetic patients with COVID-19 need more attention and better glycemic control Xu, Ming Yang, Wen Huang, Tao Zhou, Jun World J Diabetes Observational Study BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic disease spreading all over the world and has aroused global concerns. The increasing mortality has revealed its severity. It is important to distinguish severe patients and provide appropriate treatment and care to prevent damages. Diabetes is reported to be a common comorbidity in COVID-19 patients and associated with higher mortality. We attempted to clarify the relationship between diabetes and COVID-19 patients’ severity. AIM: To determine the role of type 2 diabetes in COVID-19 patients. METHODS: To study the relationship between diabetes and COVID-19, we retrospectively collected 61 patients’ data from a tertiary medical center in Wuhan. All the patients were diagnosed with laboratory-confirmed COVID-19 and admitted to the center from February 13 to March 1, 2020. Patients’ age, sex, laboratory tests, chest computed tomography findings, capillary blood glucose (BG), and treatments were collected and analyzed. Fisher exact test was used for categorical data. Univariate and multivariate logistic regressions were used to explore the relationship between clinical characteristics and patients’ severity. RESULTS: In the 61 patients, the comorbidity of type 2 diabetes, hypertension, and heart diseases were 24.6% (15 out of 61), 37.7% (23 out of 61), and 11.5% (7 out of 61), respectively. The diabetic group was related to more invasive treatments (P = 0.02) and severe status (P = 0.003). In univariate logistic regression, histories of diabetes (OR = 7.13, P = 0.003), hypertension (OR = 3.41, P = 0.039), and hepatic dysfunction (OR = 7.69, P = 0.002) were predictors of patients’ severity while heart disease (OR = 4.21, P = 0.083) and large lung involvement (OR = 2.70, P = 0.093) also slightly exacerbated patients’ conditions. In the multivariate analysis, diabetes (OR = 6.29, P = 0.016) and hepatic dysfunction (OR = 5.88, P = 0.018) were risk factors for severe patients. Diabetic patients showed elevated BG in 61.7% of preprandial tests and 33.3% of postprandial tests, revealing the limited control of glycemia in COVID-19 patients. CONCLUSION: A history of type 2 diabetes is correlated with invasive treatments and severe status. Suboptimal glycemic control and hepatic dysfunction have negative effects on severity status and may lead to the exacerbation of COVID-19 patients. Baishideng Publishing Group Inc 2020-12-15 2020-12-15 /pmc/articles/PMC7754170/ /pubmed/33384770 http://dx.doi.org/10.4239/wjd.v11.i12.644 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Observational Study Xu, Ming Yang, Wen Huang, Tao Zhou, Jun Diabetic patients with COVID-19 need more attention and better glycemic control |
title | Diabetic patients with COVID-19 need more attention and better glycemic control |
title_full | Diabetic patients with COVID-19 need more attention and better glycemic control |
title_fullStr | Diabetic patients with COVID-19 need more attention and better glycemic control |
title_full_unstemmed | Diabetic patients with COVID-19 need more attention and better glycemic control |
title_short | Diabetic patients with COVID-19 need more attention and better glycemic control |
title_sort | diabetic patients with covid-19 need more attention and better glycemic control |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754170/ https://www.ncbi.nlm.nih.gov/pubmed/33384770 http://dx.doi.org/10.4239/wjd.v11.i12.644 |
work_keys_str_mv | AT xuming diabeticpatientswithcovid19needmoreattentionandbetterglycemiccontrol AT yangwen diabeticpatientswithcovid19needmoreattentionandbetterglycemiccontrol AT huangtao diabeticpatientswithcovid19needmoreattentionandbetterglycemiccontrol AT zhoujun diabeticpatientswithcovid19needmoreattentionandbetterglycemiccontrol |